Nov 23 |
Cannabidiol for COVID-19: real-time meta analysis of 8 studies | |
| Meta analysis using the most serious outcome reported shows 12% [-33‑86%] higher risk, without reaching statistical significance. While non-symptomatic case results show 8% [-14‑25%] improvement, symptomatic results .. | ||
Jun 21 |
et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2024.17977 | Cannabis, Tobacco Use, and COVID-19 Outcomes |
| 3% lower mortality (p=0.73), 27% higher ICU admission (p<0.0001), and 80% higher hospitalization (p<0.0001). Retrospective 72,501 COVID-19 patients in the USA showing cannabis use associated with higher risk of hospitalization and ICU admission. | ||
Dec 30 2023 |
et al., Journal of Clinical Medicine, doi:10.3390/jcm13010227 | Cannabinoids and the Endocannabinoid System in Early SARS-CoV-2 Infection and Long COVID-19—A Scoping Review |
| Review of the potential therapeutic role of cannabinoids and the endocannabinoid system in SARS-CoV-2 infection and long COVID-19. Authors note that early in infection, cannabinoids may prevent viral entry, mitigate oxidative stress, and .. | ||
Jan 28 2023 |
et al., SSRN Electronic Journal, doi:10.2139/ssrn.4336513 | Cannabis Use and COVID-19 Hospitalization Outcomes. A Retrospective Study |
| 56% lower mortality (p<0.0001), 25% lower ventilation (p<0.0001), and 6% longer hospitalization (p=0.0009). Retrospective 1,657,800 COVID-19 hospitalizations in the USA including 13,095 patients with cannabis use disorder, showing lower risk of mortality with cannabis use disorder. The text and Table S2 have conflicting results for mortality: 0.. | ||
Aug 29 2022 |
et al., The Journal of Clinical Psychiatry, doi:10.4088/JCP.21m14332 | Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes |
| 47% higher hospitalization (p=0.0001). Retrospective 6,291 COVID-19 patients in the USA, showing higher mean hospital admissions and higher maximum length of hospitalization with cannabis use disorder. Results for cannabis use disorder patients may differ from other use of can.. | ||
Aug 5 2022 |
et al., Journal of Cannabis Research, doi:10.1186/s42238-022-00152-x | Cannabis consumption is associated with lower COVID-19 severity among hospitalized patients: a retrospective cohort analysis |
| 2% lower mortality (p=0.57), 5% lower ventilation (p=0.02), 9% lower ICU admission (p=0.02), and 3% lower need for oxygen therapy (p=0.27). Retrospective 1,831 hospitalized COVID-19 patients in the USA, showing lower mechanical ventilation and ICU admission, but no significant difference in mortality. | ||
Jun 22 2022 |
et al., Chronic Diseases and Translational Medicine, doi:10.1002/cdt3.38 | Association of cannabis with chronic obstructive pulmonary disease and COVID-19 infection |
| 24% more cases (p=0.009). UK Biobank retrospective showing a higher risk of COVID-19 cases with a history of cannabis use. | ||
Mar 31 2022 |
et al., Addictive Behaviors, doi:10.1016/j.addbeh.2021.107170 | Concurrent use of e-cigarettes and cannabis and associated COVID-19 symptoms, testing, and diagnosis among student e-cigarette users at four U.S. Universities |
| 212% more symptomatic cases (p<0.0001) and 3% more cases (p=0.33). Retrospective 800 e-cigarette users in the USA, showing higher risk of COVID-19 diagnosis and symptoms with cannabis use. | ||
Mar 8 2022 |
et al., Frontiers in Public Health, doi:10.3389/fpubh.2022.829715 | Cannabis use is associated with lower COVID-19 susceptibility but poorer survival |
| 181% higher mortality (p=0.04) and 19% fewer cases (p=0.0001). UK Biobank retrospective with 13,099 cannabis users, showing a lower risk of COVID-19 infection, however regular users had a significantly higher risk of mortality. | ||
Jan 20 2022 |
et al., Science Advances, doi:10.1126/sciadv.abi6110 (date from preprint) | Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses |
| 50% fewer cases (p=0.006). Retrospective 1,212 patients in the USA with a history of seizure-related conditions, showing patients treated with CBD100 had significantly lower incidence of COVID-19 cases compared to a matched control group. In Vitro study showing CBD.. | ||
Jan 10 2022 |
et al., Journal of Natural Products, doi:10.1021/acs.jnatprod.1c00946 | Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants |
| In Vitro study showing that cannabigerolic acid and cannabidiolic acid inhibited SARS-CoV-2 entry into cells. | ||
Oct 7 2021 |
et al., Cannabis and Cannabinoid Research, doi:10.1089/can.2021.0093 | Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial |
| 557% higher hospitalization (p=0.25) and 33% slower recovery (p=0.21). RCT 105 patients recruited in an ER in Brazil, 49 treated with CBD, showing no significant differences with treatment. 300mg CBD for 14 days. For discussion see [liebertpub.com]. | ||
Feb 17 2021 |
et al., International Journal of Molecular Sciences, doi:10.3390/ijms22041986 | Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19 |
| Review of the potential benefits and concerns for the use of cannabidiol in the treatment of COVID-19. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.